Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fanchin, R.
Right arrow Articles by Frydman, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fanchin, R.
Right arrow Articles by Frydman, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 18, No. 12, 2698-2703, December 2003
© 2003 European Society of Human Reproduction and Embryology

Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists

Renato Fanchin1,3, Laurent Salomon1, Altina Castelo-Branco1, François Olivennes1, Nelly Frydman2 and René Frydman1

Departments of 1 Obstetrics and Gynecology and Reproductive Medicine and 2 Biology and Genetics of Reproduction, Clamart, France

3 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology and Reproductive Medicine, Hôpital Antoine Béclère, 157, rue de la Porte de Trivaux, 92141 Clamart, France. e-mail: renato.fanchin{at}abc.ap-hop-paris.fr

BACKGROUND: The purpose of this study was to investigate whether luteal estradiol (E2) administration reduces follicular size discrepancies and enhances ovarian response in recombinant FSH (r-FSH)/GnRH antagonist protocols. METHODS: We studied prospectively 90 IVF-embryo transfer (ET) candidates who were randomly pre-treated with 17{beta}-E2 (4 mg/day) from day 20 until next cycle day 2 (E2 group, n = 47) or served as controls (control group, n = 43). On day 3, all women started r-FSH treatment. A single 3 mg dose of GnRH antagonist was administered eventually according to follicular maturation. Outcome measures were magnitude of size discrepancy of growing follicles on day 8 of r-FSH treatment and number of follicles >=16 mm in diameter on the day of HCG. RESULTS: On day 8, follicles were smaller (9.9 ± 2.5 versus 10.9 ± 3.4 mm, P < 0.001) and their size discrepancies attenuated (P < 0.001) in the E2 group compared with the control group. This was associated with more >=16 mm follicles, mature oocytes and embryos in the E2 group. CONCLUSIONS: Luteal E2 administration reduces the pace of growth, improves size homogeneity of antral follicles on day 8 of r-FSH treatment and increases the number of follicles reaching maturation at once. Coordination of follicular development optimizes ovarian response to r-FSH/GnRH antagonist protocols and may constitute an attractive approach to improving their outcome.

Key words: controlled ovarian stimulation/estradiol/follicular synchronization/ovarian response


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
E. Arbo, D.V. Vetori, M.F. Jimenez, F.M. Freitas, N. Lemos, and J.S. Cunha-Filho
Serum anti-mullerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills
Hum. Reprod., December 1, 2007; 22(12): 3192 - 3196.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.A. Huirne, R. Homburg, and C.B. Lambalk
Are GnRH antagonists comparable to agonists for use in IVF?
Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. Cedrin-Durnerin, B. Bstandig, I. Parneix, V. Bied-Damon, C. Avril, C. Decanter, and J.N. Hugues
Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol
Hum. Reprod., January 1, 2007; 22(1): 109 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
I. E. Messinis
Ovarian feedback, mechanism of action and possible clinical implications
Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.A. Huirne, J.N. Hugues, C. Pirard, F. Fischl, J.C. Sage, J.L. Pouly, A. Obruca, D.M. Braat, A.C.D. van Loenen, and C.B. Lambalk
Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study
Hum. Reprod., June 1, 2006; 21(6): 1408 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. M. Kolibianakis, E. G. Papanikolaou, M. Camus, H. Tournaye, A. C. Van Steirteghem, and P. Devroey
Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial
Hum. Reprod., February 1, 2006; 21(2): 352 - 357.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.